Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2025-12-24 @ 4:27 PM
NCT ID:
NCT00721266
Eligibility Criteria:
Inclusion Criteria:
* adult patients, \>=18 years of age;
* centrally confirmed EGFR expression in tumor tissue;
* radiologically measurable or clinically evaluable disease;
* last dose of systemic anti-neoplastic therapy or radiotherapy \>=28 days prior to start of study;
* histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+ solid tumors (Part 1);
* histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+ and mutant KRAS colorectal cancer (Part 2);
* not more than 2 previous cytotoxic regimens for metastatic disease (Part 2).
Exclusion Criteria:
* history of grade 3-4 toxicity resulting from previous anti-EGFR treatment;
* known or suspected CNS metastases;
* wild type KRAS colorectal cancer (Part 2).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00721266
Study Brief:
Protocol Section:
NCT00721266